IGEA Pharma N.V.

IGEA to get SIX approval to Annual Report 2022 disclosure

IGEA Pharma N.V. / Key word(s): Annual Results/Annual Results IGEA Pharma N.V.: IGEA to get SIX approval to Annual Report 2022 disclosure 01-May-2023 / 23:46 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement.

IGEA to get SIX approval to Annual Report 2022  disclosure

 

Hoofddorp, the Netherlands, 30 April 2023. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2022  Annual Report.

 

 

In accordance with SIX’s approval, this press release sets out the relevant section of the decision:

 

1. The exemption application of IGEA (Issuer) dated 28 April 2023 requesting an extension of the deadline to publish its 2022 annual report and to file such report with SIX Exchange Regulation AG until 31 May 2023 at the latest is granted with the following reservation (lit. a) and under the following conditions (lit. b and c):

 

               a. SIX Exchange Regulation AG reserves the right to suspend trading of the 
                   registered shares of the Issuer in case its 2022 annual report is not published in
                  accordance with the provisions on ad hoc publicity (Art. 53 of the Listing Rules
                 [LR]in connection with the Directive on Ad hoc Publicity [DAH]) and not filed with 
                 SIX Exchange Regulation AG until Wednesday, 31 May 2023, 11.59 pm CET, at the latest.
             b. IGEA is required to publish a notice in accordance with the provisions on ad hoc    publicity (Art.